Talus Biosciences在Two Bear Capital领投的Seed+中筹集了1120万美元的资金，用于推进治疗项目并扩大其MARMOT平台。 Talus Biosciences raises $11.2M in Seed+ funding, led by Two Bear Capital, to advance therapeutic programs and expand its MARMOT platform.

位于西雅图的药物发现公司Talus Biosciences已经筹集了1120万美元的Seed+资金, Talus Biosciences, a Seattle-based drug discovery company, has raised $11.2M in Seed+ funding, led by Two Bear Capital. 该公司将重点推进其治疗方案,如针对布拉奇鲁里驱动的癌症和与前列腺癌有牵连的不可药的转录因子。 The company will focus on advancing its therapeutic programs, such as targeting Brachyury-driven cancers and an undruggable transcription factor implicated in prostate cancer. 此外,它们还将扩大其专利的MARMOT平台,该平台包括人工智能、蛋白质组学、合成化学和计算生物学,以发现和调查规模的药物、蛋白质和基因组学。 Moreover, they will expand their proprietary MARMOT platform, which combines AI, proteomics, synthetic chemistry, and computational biology, to discover and interrogate drugs, proteins, and genomics at scale.